GlassScriptPhysician profile
Nicholas Dimassa
NPI 1508391533
$48,831.17
in general payments reported to CMS, 2019-2025
23 companies · $17K in 2025
The $17K reported for 2025 was more than what 97% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,686 · 2021: $3,450 · 2022: $5,528 · 2023: $9,443 · 2024: $12K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Travel and Lodging: $6,972 · Food and Beverage: $2,365 · Consulting Fee: $615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,215.00 |
| Travel and Lodging | $6,971.97 |
| Food and Beverage | $2,365.37 |
| Consulting Fee | $615.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acumed LLC | $37,961.35 | 2022-2025 | Osteomed, Acumed, Acumed |
| Mid-Atlantic Surgical Systems, LLC | $5,647.28 | 2020-2024 | |
| Arthrex, INC. | $2,081.76 | 2020-2024 | |
| Stryker Corporation | $716.32 | 2022 | |
| Misonix INC | $493.32 | 2020-2021 | |
| Smith+Nephew, INC. | $420.05 | 2021-2024 | Stravix, Stravix Pl, Collagenase Santyl |
| Bioventus LLC | $390.29 | 2022-2025 | Theragenesis Bilayer Wound Matrix, Exogen Ultrasound Bone Healing System |
| Lifenet Health | $270.38 | 2024 | Theragenesis Wound Matrix |
| Depuy Synthes Sales INC. | $198.00 | 2021-2025 | Motoband, Motoband Cp |
| Extremity Medical | $136.27 | 2024 | |
| Melinta Therapeutics, LLC | $108.59 | 2023 | Kimyrsa |
| Axogen | $81.24 | 2025 | |
| Averitas Pharma INC. | $73.09 | 2023-2025 | Qutenza |
| Grt US Holding, INC. | $41.49 | 2022 | |
| Abbott Laboratories | $37.80 | 2024 | Proclaim |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $34.18 | 2024 | Senza |
| Heron Therapeutics, INC. | $30.99 | 2022-2023 | Zynrelef |
| Paragon 28, INC. | $27.50 | 2023 | Silverback |
| Vertex Pharmaceuticals Incorporated | $20.94 | 2025 | |
| Merck Sharp & Dohme LLC | $19.65 | 2023 | Bridion |
| Triad Life Sciences INC. | $19.10 | 2022 | |
| Organogenesis INC. | $16.24 | 2024 | |
| Microaire Surgical Instruments LLC | $5.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Dimassa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.